You are here: Industry Insights > Roche

News List

WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19 WorldPharmaNews
February 15, 2022
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Actemra®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification.
Roche gets FDA priority review for Evrysdi to treat SMA in new-borns pharmaceutical-business-review
January 27, 2022
Swiss healthcare company Roche has received the US Food and Drug Administration (FDA) priority review for its Evrysdi...
European Commission approves Actemra/RoActemra by Roche to treat severe COVID-19 expresspharma
December 13, 2021
Approval based on results from four phase-III studies in more than 5,500 patients
EMA Expands Authorization for Roche’s Actemra/RoActemra in COVID contractpharma
December 08, 2021
An accelerated assessment by the EMA’s CHMP reviewed results from four studies of Actemra/RoActemra in over 5,500 patients with severe or critical COVID-19.
EMA CHMP recommends granting approval for Roche’s therapy to treat Covid-19 Pharmaceutical-Technology
December 08, 2021
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended EU marketing authorisation for Roche’s Actemra/RoActemra (tocilizumab) to treat adult Covid-19 patients.
Roche completed the repurchase of Roche shares from Novartis WorldPharmaNews
December 07, 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it completed the repurchase of Roche shares that had been held by Novartis. On 4 November 2021, Roche and Novartis had announced this repurchase. The Extraordinary General Meeting of Roche Holding...
EC approves Roche’s Ronapreve for Covid-19 treatment Pharmaceutical-Business-Review
November 16, 2021
The European Commission (EC) has granted marketing authorisation for Roche’s Ronapreve to treat non-hospitalised Covid-19 patients aged 12 years and above.
CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease WorldPharmaNews
November 12, 2021
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of the antibody...
US FDA grants priority review to Roche’s Tecentriq as adjuvant treatment for non-small cell lung cancer expresspharma
August 04, 2021
Tecentriq is the first and only cancer immunotherapy to demonstrate positive phase-III results in the adjuvant lung cancer setting.
Roche’s Evrysdi significantly improves lives of babies with SMA europeanpharmaceuticalreview
August 02, 2021
The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page